News

Filter

Current filters:

Astellas PharmaFinancial

1 to 9 of 21 results

Astellas links with Mitokyne on mitochondria-related therapies

Astellas links with Mitokyne on mitochondria-related therapies

07-10-2013

Japanese drug major Astellas Pharma and USA-based start-up Mitokyne have entered into an exclusive R&D…

Astellas PharmaFinancialLicensingMergers & AcquisitionsMitokynePharmaceuticalResearch

AVEO Oncology restructuring and job cuts as tivozanib future in RCC in doubt

05-06-2013

Following a recent negative opinion on its lead product candidate from a Food and Drug Administration…

Astellas PharmaAVEO OncologyBiotechnologyFinancialManagementOncologyResearchtivozanib

Astellas reorganizes research framework, including closing OSI Pharma and Perseid

15-05-2013

Japanese drug major Astellas Pharma (TYO: 4503) has announced plans to reshape its research framework…

Astellas PharmaFinancialManagementOSI PharmaceuticalsPerseid TherapeuticsPharmaceuticalResearch

MHLW joins Japan's first P-PP to facilitate R&D of new health technologies for the developing world

08-04-2013

The Japanese Ministry of Health, Labor and Welfare (MHLW) has said it supports the research and development…

Asia-PacificAstellas PharmaDaiichi SankyoEisaiFinancialHealthcarePharmaceuticalResearchShionogiTakeda PharmaceuticalsTropical diseases

Takeda's leadership as Japan's largest drugmaker set to decline, says DR

29-10-2012

Based on full-year 2011 sales, Japan's Takeda Pharmaceutical (TYO: 4502) maintained its position as the…

Asia-PacificAstellas PharmaFinancialPharmaceuticalResearchTakeda Pharmaceuticals

Astellas links with KEK on tropical diseases; Upgraded by CS analysts

25-09-2012

Japanese drug major Astellas Pharma (TYO: 4503) has entered into a collaboration with the High Energy…

Astellas PharmaFinancialGenito-urinaryMyrbetriqOncologyPharmaceuticalResearchTropical diseasesXtandi

Optimer earns 10 million-euro milestone as Astellas debuts Dificlir in Europe

11-06-2012

USA-Based Optimer Pharmaceuticals (Nasdaq: OPTR) says that it is set to receive 10 million euros ($12.5…

Antibiotics and Infectious diseasesAstellas PharmaDificlirEuropeFinancialLicensingOptimer PharmaceuticalsPharmaceutical

1 to 9 of 21 results

COMPANY SPOTLIGHT

Menarini

Back to top